Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt: 2022-2024

Historic Convertible Debt for ImmunityBio (IBRX) over the last 3 years, with Dec 2024 value amounting to $461.9 million.

  • ImmunityBio's Convertible Debt fell 14.83% to $500.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $500.8 million, marking a year-over-year decrease of 14.83%. This contributed to the annual value of $461.9 million for FY2024, which is 19.95% down from last year.
  • Per ImmunityBio's latest filing, its Convertible Debt stood at $461.9 million for FY2024, which was down 19.95% from $577.0 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Convertible Debt peaked at $577.0 million during FY2023, and registered a low of $241.3 million during FY2022.
  • Its 3-year average for Convertible Debt is $426.7 million, with a median of $461.9 million in 2024.
  • In the last 5 years, ImmunityBio's Convertible Debt surged by 139.13% in 2023 and then fell by 19.95% in 2024.
  • Over the past 3 years, ImmunityBio's Convertible Debt (Yearly) stood at $241.3 million in 2022, then skyrocketed by 139.13% to $577.0 million in 2023, then declined by 19.95% to $461.9 million in 2024.